How to buy DBV Technologies S-A stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy DBV Technologies S-A stock

Own DBV Technologies S-A stock in just a few minutes.

DBV Technologies S.A is a biotechnology business based in the US. DBV Technologies S-A shares (DBVT) are listed on the NASDAQ and all prices are listed in US Dollars. DBV Technologies S-A employs 141 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in DBV Technologies S-A

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DBVT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

DBV Technologies S-A share price

Use our graph to track the performance of DBVT stocks over time.

DBV Technologies S-A shares at a glance

Information last updated 2021-04-15.
52-week range$1.35 - $7.00
50-day moving average $5.50
200-day moving average $3.81
Wall St. target price$9.73
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.27

Buy DBV Technologies S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy DBV Technologies S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DBV Technologies S-A financials

Revenue TTM $11.3 million
Gross profit TTM $11.3 million
Return on assets TTM -31.09%
Return on equity TTM -80.04%
Profit margin 0%
Book value $1.87
Market capitalisation $726.2 million

TTM: trailing 12 months

Shorting DBV Technologies S-A shares

There are currently 1.9 million DBV Technologies S-A shares held short by investors – that's known as DBV Technologies S-A's "short interest". This figure is 40.7% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting DBV Technologies S-A shares can be evaluated.

DBV Technologies S-A's "short interest ratio" (SIR)

DBV Technologies S-A's "short interest ratio" (SIR) is the quantity of DBV Technologies S-A shares currently shorted divided by the average quantity of DBV Technologies S-A shares traded daily (recently around 137472.84390592). DBV Technologies S-A's SIR currently stands at 14.03. In other words for every 100,000 DBV Technologies S-A shares traded daily on the market, roughly 14030 shares are currently held short.

However DBV Technologies S-A's short interest can also be evaluated against the total number of DBV Technologies S-A shares, or, against the total number of tradable DBV Technologies S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DBV Technologies S-A's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 DBV Technologies S-A shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable DBV Technologies S-A shares, roughly 0 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against DBV Technologies S-A.

Find out more about how you can short DBV Technologies S-A stock.

DBV Technologies S-A share dividends

We're not expecting DBV Technologies S-A to pay a dividend over the next 12 months.

DBV Technologies S-A share price volatility

Over the last 12 months, DBV Technologies S-A's shares have ranged in value from as little as $1.35 up to $7. A popular way to gauge a stock's volatility is its "beta".

DBVT.US volatility(beta: 2.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DBV Technologies S-A's is 2.1744. This would suggest that DBV Technologies S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.

DBV Technologies S-A overview

DBV Technologies S. A. , a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site